Skip to main content
Premium Trial:

Request an Annual Quote

PierianDx Raises $3M in New Funding, Seeks $2M More

CHICAGO (GenomeWeb) - Bioinformatics startup PierianDx has raised a little more than $3 million in new investment from unspecified sources, according to a filing with the US Securities and Exchange Commission. The total planned size of the offering is $5 million in equity and options, the St. Louis-based company disclosed this week.

PierianDx, which spun out of Washington University in 2014, offers a WUSTL-developed software tool called Clinical Genomicist Workstation to help clinical laboratories manage next-generation sequencing data. Since last fall, the software also has supported clinical microarray technology.

The company also provides cloud hosting, a bioinformatics database, clinical interpretation, and related consulting services.

This is the first known new investment in PierianDx since a $9.25 million Series A round of venture capital announced in early 2016. Health Catalyst Capital Management led that round, with participation from the  Inova Translational Medicine Institute, ARUP Laboratories, and an affiliate of Ocean Road Advisors.

PierianDx, which has not disclosed its annual revenues, has made one acquisition, purchasing bioinformatics vendor Tute Genomics in September 2016.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.